Table 1.
Serum content of vitamin D and correlations with patient and disease factors
| n (%) | 25(OH)D (mean ± SE), nmol/L | r | p a | p b | ||
|---|---|---|---|---|---|---|
| Median age (range), years | 58.5 (30–73) | 84 (100) | 0.079 | 0.48 | 0.45 | |
| Sex | Female | 34 (40.5) | 60.2 ± 4.2 | |||
| Male | 50 (59.5) | 58.4 ± 3.1 | 0.72 | 0.76 | ||
| BMI (mean ± SD), kg/m2 | 24.1 ± 3.5 | 83 (98.8) | −0.046 | 0.68 | 0.60 | |
| ECOG | 0 | 67 (79.8) | 61.8 ± 2.7 | |||
| 1 | 17 (20.2) | 48.5 ± 5.6 | 0.031 | 0.015 | ||
| Hemoglobin | Normal | 63 (75.0) | 63.2 ± 2.7 | |||
| Anemicc | 21 (25.0) | 47.0 ± 5.1 | 0.004 | 0.029 | ||
| Median tumor volume (range), cm3 | 16.7 (1.0–293)d | 71 (84.5) | −0.267 | 0.025 | 0.024 | |
| T stage | 2–3 | 53 (63.1) | 63.0 ± 3.1 | |||
| 4 | 31 (36.9) | 52.5 ± 3.9 | 0.040 | 0.028 | ||
| N stage | 0 | 11 (13.1) | 62.1 ± 7.7 | |||
| 1–2 | 73 (86.9) | 58.7 ± 2.6 | 0.65 | 0.95 | ||
| ypT stagee | 0–3 | 66 (78.5) | 62.4 ± 2.7 | |||
| 4 | 17 (20.2) | 48.1 ± 5.6 | 0.019 | 0.018 | ||
| ypN stagee | 0 | 56 (66.7) | 61.2 ± 3.3 | |||
| 1–2 | 27 (32.1) | 55.9 ± 3.5 | 0.33 | 0.21 |
Abbreviations: 25(OH)D 25-hydroxyvitamin D, BMI body mass index, ECOG Eastern Cooperative Oncology Group performance status, SD standard deviation, SE standard error, TN tumor-node, yp histologic response to neoadjuvant therapy
aDescribed by Pearson correlation test or independent sample t-test
bEstimated by linear and logistic regression models, with winter/spring and summer/fall as collapsed categories
cAnemia was defined as hemoglobin level below the lower reference interval limit used in Norway (< 11.7 g/dL for women and < 13.4 g/dL for men)
dThe data were log-transformed before analysis
eOne patient died unexpectedly before pelvic surgery; as a consequence, histologic tumor response data was missing, and the single case was omitted from these analyses